Monthly information relating to the total number of voting rights and shares making up the share capital


Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.

Article 223-16 of the general regulations of the Autorité des marchés financiers

(AMF – Financial Markets Authority)

LYON, France–(BUSINESS WIRE)–Regulatory News:

Maat Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech pioneer in the development of microbiome-based ecosystem therapies dedicated to improving cancer patient survival outcomespublishes today the number of shares making up the share capital and the total number of voting rights (article L. 233-8 of the French Commercial Code and article 223-16 of the general regulations of the Autorité des marchés financiers) (AMF) ) on March 31, 2022.

Place of registration: Euronext Paris

ISIN code: FR0012634822



Total number of shares making up the share capital

Total number of

theoretical voting rights(1)

Total number of effective voting rights(2)





(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares whose voting rights have been granted. been suspended.

(2) Effective voting rights correspond to the total number of voting rights that can be used at the General Meeting. The total number of effective voting rights is calculated without taking into account the shares whose voting rights are suspended.

Modification of the 2022 financial calendar

MaaT Pharma has decided to slightly modify its calendar for two financial announcements:

  • The publication of the press release relating to the 2021 annual results will be brought forward and will take place on Thursday April 14, 2022, instead of Friday April 15, 2022, as previously communicated to the market.

  • The Annual General Meeting has been moved to Tuesday May 31, 2022, instead of Monday May 23, 2022, as previously communicated to the market.

Provisional financial calendar*

• April 14, 2022 – 2021 annual results

• May 05, 2022 – Q1 revenue and cash position

• May 31, 2022 – Annual General Meeting

• July 28, 2022 – Revenue and cash position, 2nd quarter

• September 29, 2022 – 2022 half-year results

• November 08, 2022 – Quarter 3 revenue and cash position

*Indicative timetable subject to change.

About MaaT Pharma

MaaT Pharma, a clinical-stage biotechnology company, has implemented a comprehensive approach to restore the patient-microbiome symbiosis in oncology. Committed to the treatment of cancer and graft versus host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already obtained proof of concept in a phase II clinical trial in GvHD acute. Its powerful discovery and analytics platform, gutPrint®, supports the development and expansion of its pipeline by determining new disease targets, evaluating drug candidates and identifying biomarkers for microbiome-related conditions.

The Company’s microbiome ecosystem therapies are produced under a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-renowned scientists and established relationships with regulatory bodies to support the integration of the use of microbiome therapies into clinical practice.

MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since November 2021.

Maat Pharma


Co-founder and CEO

Siân Crouzet, COO/CFO

+33 4 28 29 14 00

MaaT Pharma – Media Relations


Senior Manager of Public Relations and Corporate Communications

+33 6 07 55 25 36

Trophic communications

Business communication



+49 89 23 88 77 31

Source: MaaT Pharma


Comments are closed.